Topoisomerase I Inhibitors
"Topoisomerase I Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
| Descriptor ID |
D059004
|
| MeSH Number(s) |
D27.505.519.389.892.500 D27.505.954.248.794.500
|
| Concept/Terms |
Topoisomerase I Inhibitors- Topoisomerase I Inhibitors
- Inhibitors, Topoisomerase I
- Topoisomerase 1 Inhibitors
- Inhibitors, Topoisomerase 1
- DNA Topoisomerase I Inhibitors
- DNA Type 1 Topoisomerase Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase I Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase I Inhibitors".
This graph shows the total number of publications written about "Topoisomerase I Inhibitors" by people in this website by year, and whether "Topoisomerase I Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase I Inhibitors" by people in Profiles.
-
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025 Oct; 31(10):3504-3513.
-
Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity. Int J Nanomedicine. 2019; 14:3799-3817.
-
Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. Eur J Cancer. 2017 02; 72:166-176.
-
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5.
-
Topoisomerase 1 and single-strand break repair modulate transcription-induced CAG repeat contraction in human cells. Mol Cell Biol. 2011 Aug; 31(15):3105-12.
-
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan. Glycoconj J. 2010 Jan; 27(1):27-38.
-
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 2008 May; 10(5):489-500.
-
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9.
-
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res. 2006 Jan 15; 12(2):556-62.
-
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature. 2005 Mar 03; 434(7029):108-13.